Form 4: ARTIVION Director James Bullock Receives Equity Grant as Part of Incentive Plan

ARTIVION, Inc. Director James Bullock was granted 6,325 shares of common stock on May 22, 2025, as part of the company's Equity and Cash Incentive Plan.

Summary

• James Bullock, a Director of ARTIVION, INC. (Ticker: AORT), acquired 6,325 shares of Common Stock on May 22, 2025.
• The acquisition was a grant, with a reported price of $0 per share, indicating it was likely a Restricted Stock Award (RSA).
• These 6,325 RSA shares are scheduled to vest on May 22, 2026, in accordance with the terms of the company's Equity and Cash Incentive Plan.
• Following this transaction, James Bullock beneficially owns a total of 68,647 shares of ARTIVION, INC. Common Stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive sign of aligning management's interests with long-term shareholder value, as the director's compensation becomes tied to the company's future performance. It represents a standard and expected compensation practice.

Positives

• Director James Bullock received an equity grant of 6,325 shares, which aligns his interests with long-term shareholder value.
• The grant is part of the company's established Equity and Cash Incentive Plan, indicating a structured approach to executive and board compensation and retention.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is a common practice across various industries to align the interests of company leadership with those of shareholders. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of Restricted Stock Awards (RSAs) to directors is a standard compensation practice in publicly traded companies across various sectors, including the medical device industry where Artivion operates. This method is widely used to incentivize long-term performance and retention by tying a portion of compensation directly to the company's stock performance.
• While specific comparable companies or projects are not mentioned in the filing, such equity grants are consistent with compensation structures observed in peers within the healthcare and medical technology sectors, aiming to align director incentives with shareholder value creation over time.

Related Party Transactions

• The transaction involves an equity grant to James Bullock, a Director of Artivion Inc., which is a related party transaction as part of his compensation under the company's incentive plan.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns management's interests with long-term shareholder value, as the director's compensation is tied to the company's stock performance, potentially fostering more prudent decision-making.

Next Steps

• The 6,325 Restricted Stock Award shares are scheduled to vest on May 22, 2026.

Key Dates

Recommendation

Keywords

ARTIVION, AORT, Form 4, Insider Transaction, Stock Grant, Restricted Stock Award, Equity Incentive Plan, Director Compensation, James Bullock